Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Small-Cell Lung Cancer-Pipeline Review, H1 2015

Small-Cell Lung Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Small-Cell Lung Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Small-Cell Lung Cancer-Pipeline Review, H1 2015', provides an overview of the Small-Cell Lung Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Small-Cell Lung Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Small-Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Small-Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Small-Cell Lung Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Small-Cell Lung Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Small-Cell Lung Cancer Overview 11

Therapeutics Development 12

Pipeline Products for Small-Cell Lung Cancer-Overview 12

Pipeline Products for Small-Cell Lung Cancer-Comparative Analysis 13

Small-Cell Lung Cancer-Therapeutics under Development by Companies 14

Small-Cell Lung Cancer-Therapeutics under Investigation by Universities/Institutes 20

Small-Cell Lung Cancer-Pipeline Products Glance 21

Late Stage Products 21

Clinical Stage Products 22

Early Stage Products 23

Unknown Stage Products 24

Small-Cell Lung Cancer-Products under Development by Companies 25

Small-Cell Lung Cancer-Products under Investigation by Universities/Institutes 32

Small-Cell Lung Cancer-Companies Involved in Therapeutics Development 33

A. Menarini Industrie Farmaceutiche Riunite Srl 33

AbbVie Inc. 34

Alchemia Limited 35

Amgen Inc. 36

Aposense Ltd. 37

Array BioPharma Inc. 38

Astellas Pharma Inc. 39

AstraZeneca Plc 40

AVEO Pharmaceuticals, Inc. 41

Bayer AG 42

BIND Therapeutics, Inc. 43

Blend Therapeutics, Inc. 44

Boehringer Ingelheim GmbH 45

Bristol-Myers Squibb Company 46

Cantex Pharmaceuticals, Inc. 47

Celator Pharmaceuticals, Inc. 48

CellAct Pharma GmbH 49

Cerulean Pharma, Inc. 50

Cornerstone Pharmaceuticals, Inc. 51

Critical Outcome Technologies Inc. 52

CytRx Corporation 53

Eisai Co., Ltd. 54

Eli Lilly and Company 55

Exelixis, Inc. 56

F. Hoffmann-La Roche Ltd. 57

GlaxoSmithKline Plc 58

Hutchison MediPharma Limited 59

ImmunoCellular Therapeutics, Ltd. 60

Immunomedics, Inc. 61

Inbiopro Solutions Pvt. Ltd. 62

Johnson & Johnson 63

Karyopharm Therapeutics, Inc. 64

Kolltan Pharmaceuticals, Inc. 65

Kyowa Hakko Kirin Co., Ltd. 66

Lindis Biotech GmbH 67

MabVax Therapeutics Holdings, Inc. 68

MedImmune, LLC 69

MEI Pharma, Inc. 70

Merck & Co., Inc. 71

Mersana Therapeutics, Inc. 72

Millennium Pharmaceuticals, Inc. 73

Mirna Therapeutics, Inc. 74

MolMed S.p.A. 75

Mologen AG 76

Nektar Therapeutics 77

Neotropix, Inc. 78

Nippon Kayaku Co., Ltd. 79

Novartis AG 80

Omnitura Therapeutics Inc. 81

OncoMed Pharmaceuticals, Inc. 82

Ono Pharmaceutical Co., Ltd. 83

Onxeo SA 84

Onyx Pharmaceuticals, Inc. 85

Oxford BioTherapeutics Ltd 86

Pfizer Inc. 87

Polaris Pharmaceuticals, Inc. 88

Rexahn Pharmaceuticals, Inc. 89

Spectrum Pharmaceuticals, Inc. 90

Sumitomo Dainippon Pharma Co., Ltd. 91

Synta Pharmaceuticals Corp. 92

Tesaro, Inc. 93

Vertex Pharmaceuticals Incorporated 94

Zensun (Shanghai) Sci & Tech Co., Ltd. 95

ZIOPHARM Oncology, Inc. 96

Small-Cell Lung Cancer-Therapeutics Assessment 97

Assessment by Monotherapy Products 97

Assessment by Combination Products 98

Assessment by Target 99

Assessment by Mechanism of Action 107

Assessment by Route of Administration 113

Assessment by Molecule Type 115

Drug Profiles 117

(irinotecan hydrochloride + cisplatin)-Drug Profile 117

5B1-Drug Profile 118

ABT-737-Drug Profile 119

Adva-27a-Drug Profile 121

aldoxorubicin hydrochloride-Drug Profile 123

alisertib-Drug Profile 126

amrubicin hydrochloride-Drug Profile 130

ATT-11T-Drug Profile 132

AV-203-Drug Profile 133

AZD-2811-Drug Profile 134

AZD-3965-Drug Profile 135

belinostat-Drug Profile 137

binimetinib-Drug Profile 140

BIW-8962-Drug Profile 145

BMS-986012-Drug Profile 146

BMS-986158-Drug Profile 148

BTP-277-Drug Profile 149

cabozantinib s-malate-Drug Profile 150

CAP-7.1-Drug Profile 153

carboplatin-Drug Profile 155

carfilzomib-Drug Profile 156

Cell Therapy 1 for Oncology-Drug Profile 160

COTI-2-Drug Profile 161

COTI-219-Drug Profile 164

COTI-4-Drug Profile 165

COTI-58-Drug Profile 166

CPI-613-Drug Profile 167

CRLX-101-Drug Profile 169

CX-01-Drug Profile 171

Cyt-PLAT-Drug Profile 173

durvalumab + tremelimumab-Drug Profile 174

erismodegib-Drug Profile 176

etirinotecan pegol-Drug Profile 179

etoposide phosphate next generation-Drug Profile 182

ganetespib-Drug Profile 183

ganitumab-Drug Profile 187

GSK-2879552-Drug Profile 190

HMPL-453-Drug Profile 191

IBPM-002BZ-Drug Profile 192

ICT-109-Drug Profile 193

indisulam-Drug Profile 195

ipilimumab-Drug Profile 196

irinotecan hydrochloride-Drug Profile 200

JNJ-42756493-Drug Profile 202

KIT-SG3227-Drug Profile 204

LOP-628-Drug Profile 206

LY-2510924-Drug Profile 207

ME-344-Drug Profile 208

MGN-1703-Drug Profile 210

MK-2206 + selumetinib sulfate-Drug Profile 213

Monoclonal Antibodies to Inhibit Vasopressin V2 Receptor for Small-Cell Lung Cancer-Drug Profile 215

MRX-34-Drug Profile 216

MX-225-Drug Profile 218

NGR-hTNF-Drug Profile 219

nintedanib-Drug Profile 223

niraparib-Drug Profile 228

nivolumab-Drug Profile 230

NK-012-Drug Profile 236

NTX-010-Drug Profile 238

olaparib-Drug Profile 240

OMN-54-Drug Profile 244

OSI-930-Drug Profile 246

OX-004-Drug Profile 247

palifosfamide-Drug Profile 248

pegargiminase-Drug Profile 250

pembrolizumab-Drug Profile 253

PF-4989216-Drug Profile 260

Recombinant Peptide to Target EGFR for Oncology-Drug Profile 261

RG-6016-Drug Profile 262

rilotumumab-Drug Profile 264

roniciclib-Drug Profile 266

RX-3117-Drug Profile 268

sabarubicin-Drug Profile 269

sacituzumab govitecan-Drug Profile 271

SC-16LD6.5-Drug Profile 272

selinexor-Drug Profile 273

Small Molecules for Small Cell Lung Cancer-Drug Profile 278

Small Molecules to Inhibit EZH2-EED for Cancer-Drug Profile 279

solitomab-Drug Profile 280

STA-128666-Drug Profile 281

STA-129183-Drug Profile 283

taladegib-Drug Profile 284

tarextumab-Drug Profile 285

temozolomide-Drug Profile 287

TF-2-Drug Profile 289

topotecan hydrochloride liposomal-Drug Profile 291

Tozaride-Drug Profile 292

TRBS-07-Drug Profile 294

Vaccine for Small Cell Lung Cancer-Drug Profile 295

vandetanib-Drug Profile 297

veliparib-Drug Profile 303

vinorelbine tartrate liposomal-Drug Profile 306

vorinostat-Drug Profile 308

VX-970-Drug Profile 312

X-396-Drug Profile 313

XMT-1001-Drug Profile 314

ZS-05-Drug Profile 316

Small-Cell Lung Cancer-Recent Pipeline Updates 317

Small-Cell Lung Cancer-Dormant Projects 481

Small-Cell Lung Cancer-Discontinued Products 486

Small-Cell Lung Cancer-Product Development Milestones 488

Featured News & Press Releases 488

Appendix 496

Methodology 496

Coverage 496

Secondary Research 496

Primary Research 496

Expert Panel Validation 496

Contact Us 496

Disclaimer 497

List of Tables

Number of Products under Development for Small-Cell Lung Cancer, H1 2015 19

Number of Products under Development for Small-Cell Lung Cancer-Comparative Analysis, H1 2015 20

Number of Products under Development by Companies, H1 2015 22

Number of Products under Development by Companies, H1 2015 (Contd..1) 23

Number of Products under Development by Companies, H1 2015 (Contd..2) 24

Number of Products under Development by Companies, H1 2015 (Contd..3) 25

Number of Products under Development by Companies, H1 2015 (Contd..4) 26

Number of Products under Investigation by Universities/Institutes, H1 2015 27

Comparative Analysis by Late Stage Development, H1 2015 28

Comparative Analysis by Clinical Stage Development, H1 2015 29

Comparative Analysis by Early Stage Development, H1 2015 30

Comparative Analysis by Unknown Stage Development, H1 2015 31

Products under Development by Companies, H1 2015 32

Products under Development by Companies, H1 2015 (Contd..1) 33

Products under Development by Companies, H1 2015 (Contd..2) 34

Products under Development by Companies, H1 2015 (Contd..3) 35

Products under Development by Companies, H1 2015 (Contd..4) 36

Products under Development by Companies, H1 2015 (Contd..5) 37

Products under Development by Companies, H1 2015 (Contd..6) 38

Products under Investigation by Universities/Institutes, H1 2015 39

Small-Cell Lung Cancer-Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 40

Small-Cell Lung Cancer-Pipeline by AbbVie Inc., H1 2015 41

Small-Cell Lung Cancer-Pipeline by Alchemia Limited, H1 2015 42

Small-Cell Lung Cancer-Pipeline by Amgen Inc., H1 2015 43

Small-Cell Lung Cancer-Pipeline by Aposense Ltd., H1 2015 44

Small-Cell Lung Cancer-Pipeline by Array BioPharma Inc., H1 2015 45

Small-Cell Lung Cancer-Pipeline by Astellas Pharma Inc., H1 2015 46

Small-Cell Lung Cancer-Pipeline by AstraZeneca Plc, H1 2015 47

Small-Cell Lung Cancer-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 48

Small-Cell Lung Cancer-Pipeline by Bayer AG, H1 2015 49

Small-Cell Lung Cancer-Pipeline by BIND Therapeutics, Inc., H1 2015 50

Small-Cell Lung Cancer-Pipeline by Blend Therapeutics, Inc., H1 2015 51

Small-Cell Lung Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2015 52

Small-Cell Lung Cancer-Pipeline by Bristol-Myers Squibb Company, H1 2015 53

Small-Cell Lung Cancer-Pipeline by Cantex Pharmaceuticals, Inc., H1 2015 54

Small-Cell Lung Cancer-Pipeline by Celator Pharmaceuticals, Inc., H1 2015 55

Small-Cell Lung Cancer-Pipeline by CellAct Pharma GmbH, H1 2015 56

Small-Cell Lung Cancer-Pipeline by Cerulean Pharma, Inc., H1 2015 57

Small-Cell Lung Cancer-Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 58

Small-Cell Lung Cancer-Pipeline by Critical Outcome Technologies Inc., H1 2015 59

Small-Cell Lung Cancer-Pipeline by CytRx Corporation, H1 2015 60

Small-Cell Lung Cancer-Pipeline by Eisai Co., Ltd., H1 2015 61

Small-Cell Lung Cancer-Pipeline by Eli Lilly and Company, H1 2015 62

Small-Cell Lung Cancer-Pipeline by Exelixis, Inc., H1 2015 63

Small-Cell Lung Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 64

Small-Cell Lung Cancer-Pipeline by GlaxoSmithKline Plc, H1 2015 65

Small-Cell Lung Cancer-Pipeline by Hutchison MediPharma Limited, H1 2015 66

Small-Cell Lung Cancer-Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2015 67

Small-Cell Lung Cancer-Pipeline by Immunomedics, Inc., H1 2015 68

Small-Cell Lung Cancer-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 69

Small-Cell Lung Cancer-Pipeline by Johnson & Johnson, H1 2015 70

Small-Cell Lung Cancer-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 71

Small-Cell Lung Cancer-Pipeline by Kolltan Pharmaceuticals, Inc., H1 2015 72

Small-Cell Lung Cancer-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 73

Small-Cell Lung Cancer-Pipeline by Lindis Biotech GmbH, H1 2015 74

Small-Cell Lung Cancer-Pipeline by MabVax Therapeutics Holdings, Inc., H1 2015 75

Small-Cell Lung Cancer-Pipeline by MedImmune, LLC, H1 2015 76

Small-Cell Lung Cancer-Pipeline by MEI Pharma, Inc., H1 2015 77

Small-Cell Lung Cancer-Pipeline by Merck & Co., Inc., H1 2015 78

Small-Cell Lung Cancer-Pipeline by Mersana Therapeutics, Inc., H1 2015 79

Small-Cell Lung Cancer-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 80

Small-Cell Lung Cancer-Pipeline by Mirna Therapeutics, Inc., H1 2015 81

Small-Cell Lung Cancer-Pipeline by MolMed S.p.A., H1 2015 82

Small-Cell Lung Cancer-Pipeline by Mologen AG, H1 2015 83

Small-Cell Lung Cancer-Pipeline by Nektar Therapeutics, H1 2015 84

Small-Cell Lung Cancer-Pipeline by Neotropix, Inc., H1 2015 85

Small-Cell Lung Cancer-Pipeline by Nippon Kayaku Co., Ltd., H1 2015 86

Small-Cell Lung Cancer-Pipeline by Novartis AG, H1 2015 87

Small-Cell Lung Cancer-Pipeline by Omnitura Therapeutics Inc., H1 2015 88

Small-Cell Lung Cancer-Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015 89

Small-Cell Lung Cancer-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 90

Small-Cell Lung Cancer-Pipeline by Onxeo SA, H1 2015 91

Small-Cell Lung Cancer-Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 92

Small-Cell Lung Cancer-Pipeline by Oxford BioTherapeutics Ltd, H1 2015 93

Small-Cell Lung Cancer-Pipeline by Pfizer Inc., H1 2015 94

Small-Cell Lung Cancer-Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 95

Small-Cell Lung Cancer-Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015 96

Small-Cell Lung Cancer-Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 97

Small-Cell Lung Cancer-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 98

Small-Cell Lung Cancer-Pipeline by Synta Pharmaceuticals Corp., H1 2015 99

Small-Cell Lung Cancer-Pipeline by Tesaro, Inc., H1 2015 100

Small-Cell Lung Cancer-Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 101

Small-Cell Lung Cancer-Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2015 102

Small-Cell Lung Cancer-Pipeline by ZIOPHARM Oncology, Inc., H1 2015 103

Assessment by Monotherapy Products, H1 2015 104

Assessment by Combination Products, H1 2015 105

Number of Products by Stage and Target, H1 2015 107

Number of Products by Stage and Mechanism of Action, H1 2015 115

Number of Products by Stage and Route of Administration, H1 2015 121

Number of Products by Stage and Molecule Type, H1 2015 123

Small-Cell Lung Cancer Therapeutics-Recent Pipeline Updates, H1 2015 324

Small-Cell Lung Cancer-Dormant Projects, H1 2015 488

Small-Cell Lung Cancer-Dormant Projects (Contd..1), H1 2015 489

Small-Cell Lung Cancer-Dormant Projects (Contd..2), H1 2015 490

Small-Cell Lung Cancer-Dormant Projects (Contd..3), H1 2015 491

Small-Cell Lung Cancer-Dormant Projects (Contd..4), H1 2015 492

Small-Cell Lung Cancer-Discontinued Products, H1 2015 493

Small-Cell Lung Cancer-Discontinued Products (Contd..1), H1 2015 494

List of Figures

Number of Products under Development for Small-Cell Lung Cancer, H1 2015 19

Number of Products under Development for Small-Cell Lung Cancer-Comparative Analysis, H1 2015 20

Number of Products under Development by Companies, H1 2015 21

Comparative Analysis by Late Stage Development, H1 2015 28

Comparative Analysis by Clinical Stage Development, H1 2015 29

Comparative Analysis by Early Stage Products, H1 2015 30

Assessment by Monotherapy Products, H1 2015 104

Assessment by Combination Products, H1 2015 105

Number of Products by Top 10 Targets, H1 2015 106

Number of Products by Stage and Top 10 Targets, H1 2015 106

Number of Products by Top 10 Mechanism of Actions, H1 2015 114

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 114

Number of Products by Top 10 Routes of Administration, H1 2015 120

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 120

Number of Products by Top 10 Molecule Types, H1 2015 122

Number of Products by Stage and Top 10 Molecule Types, H1 2015 122

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

A. Menarini Industrie Farmaceutiche Riunite Srl

AbbVie Inc.

Alchemia Limited

Amgen Inc.

Aposense Ltd.

Array BioPharma Inc.

Astellas Pharma Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Bayer AG

BIND Therapeutics, Inc.

Blend Therapeutics, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Cantex Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc.

CellAct Pharma GmbH

Cerulean Pharma, Inc.

Cornerstone Pharmaceuticals, Inc.

Critical Outcome Technologies Inc.

CytRx Corporation

Eisai Co., Ltd.

Eli Lilly and Company

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

Hutchison MediPharma Limited

ImmunoCellular Therapeutics, Ltd.

Immunomedics, Inc.

Inbiopro Solutions Pvt. Ltd.

Johnson & Johnson

Karyopharm Therapeutics, Inc.

Kolltan Pharmaceuticals, Inc.

Kyowa Hakko Kirin Co., Ltd.

Lindis Biotech GmbH

MabVax Therapeutics Holdings, Inc.

MedImmune, LLC

MEI Pharma, Inc.

Merck & Co., Inc.

Mersana Therapeutics, Inc.

Millennium Pharmaceuticals, Inc.

Mirna Therapeutics, Inc.

MolMed S.p.A.

Mologen AG

Nektar Therapeutics

Neotropix, Inc.

Nippon Kayaku Co., Ltd.

Novartis AG

Omnitura Therapeutics Inc.

OncoMed Pharmaceuticals, Inc.

Ono Pharmaceutical Co., Ltd.

Onxeo SA

Onyx Pharmaceuticals, Inc.

Oxford BioTherapeutics Ltd

Pfizer Inc.

Polaris Pharmaceuticals, Inc.

Rexahn Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Synta Pharmaceuticals Corp.

Tesaro, Inc.

Vertex Pharmaceuticals Incorporated

Zensun (Shanghai) Sci & Tech Co., Ltd.

ZIOPHARM Oncology, Inc.

all-Cell Lung Cancer - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Small-Cell Lung Cancer Therapeutic Products under Development, Key Players in Small-Cell Lung Cancer Therapeutics, Small-Cell Lung Cancer Pipeline Overview, Small-Cell Lung Cancer Pipeline, Small-Cell Lung Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com